Patients with Shwachman-Diamond syndrome (SDS) who develop high-risk features of myeloid malignancy achieve significantly better survival rates when undergoing hematopoietic cell transplantation (HCT) before overt cancer develops, according to an international study published September 23, 2026, in The New England Journal of Medicine. Researchers found that while more than 90% of children with the rare inherited bone marrow failure syndrome survive past age 20, cumulative risks of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or bone marrow failure approach 78% by age 50, pointing to the need for proactive surveillance and pre-emptive intervention.
Long-Term Hematological Risks in Shwachman-Diamond Syndrome
Shwachman-Diamond syndrome is a rare genetic disorder requiring both parents to pass a mutated gene—most commonly the SBDS gene—to their child. While estimates place the U.S. patient population at around 400 individuals, advocacy groups suggest undiagnosed or misdiagnosed cases could push that number closer to 3,000. Although the condition can impact the pancreas, skeletal system, liver, and central nervous system, its most severe threat is the progressive development of bone marrow failure, MDS, or AML.
Led by researchers from the International SDS Research Consortium, including Kasiani Myers, MD, Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s, the study analyzed 847 cases ranging from infancy to adulthood. Data showed that while the incidence of potentially lethal malignancies is roughly 2% for five-year-olds, the cumulative risk climbs steeply across the lifespan, leaving fewer than 30% of patients surviving beyond age 50.
Survival Outcomes Following Early Versus Late Transplantation
To evaluate whether intervening before malignant transformation alters trajectories, the research team examined post-transplant survival across different disease stages. Among a cohort of 24 patients who underwent HCT after exhibiting high-risk features—such as abnormal clones of mutated bone marrow cells and progressive dysplasia—but before full-blown cancer emerged, approximately 82% were alive two years post-transplantation.
That survival rate drops markedly when transplantation is delayed until after malignancy establishes itself. Two-year survival falls to roughly 55% for patients transplanted after developing myelodysplastic syndrome, and drops further to approximately 36% for those undergoing the procedure following an acute myeloid leukemia diagnosis. According to Kasiani Myers, MD, waiting until malignancies are diagnosed may be too late.
Surveillance Strategies and Clinical Challenges
The findings emphasize the clinical value of close hematological and molecular surveillance to catch high-risk biomarkers before leukemic progression occurs. Expanding access to genetic screening can help identify infants and children with SDS earlier in life, allowing clinicians to monitor marrow health more effectively. However, researchers caution that HCT carries substantial procedural risks and high costs, meaning the findings do not mean that all patients with SDS should undergo transplantation at an early age.
Access to specialized transplantation and advanced monitoring may also prove challenging in lower-resource settings. Members of the research consortium state that further investigations are required to pinpoint the exact combination of clinical and molecular risk factors that best determine which patients warrant pre-emptive stem cell transplantation, balancing the inherent risks of the procedure against the high cumulative threat of malignant transformation.
Related reading